It’s unclear what impact a change in presidential administration will have on the proposal to widen access for those with obesity.

Mounjaro is a treatment for Type 2 diabetes that activates GIP and GLP-1 pathways to help regulate blood sugar. It’s part of ...

Eli Lilly topped the list of the 20 biggest pharmas by market cap with a more than 39% improvement year-to-date in its share ...

The stocks of companies that make the new class of drugs to treat obesity and manage diabetes were higher across the board ...

The Biden administration plans to require Medicare and Medicaid to offer coverage of weight loss medications for people seeking obesity treatment.The new rule, which was proposed by the administration ...

Novo Nordisk's Wegovy and similar drugs could see their costs significantly reduced under this plan, making them more ...

About 42% of U.S. adults are obese, the CDC says. GLP-1 medications have changed the picture for people hoping to reduce ...

Popular weight-loss drugs like Wegovy or Ozempic would be covered by Medicare or Medicaid under a newly-proposed rule by the ...

Millions of obese Americans would get access to popular weekly injectables that would help them shed pounds quickly if a $35 ...

The White House said it's moving to make the federal health insurance plans pay for anti-obesity drugs such as Novo Nordisk's Wegovy and Eli Lilly's Zepbound for people who are obese, even if they don ...

The Biden administration proposed a rule to let Medicare and Medicaid cover obesity drugs like Ozempic. Millions would ...

Should employers, patients or insurers cover the $411 billion annual cost for GLP-1 drugs? U.S. healthcare industry grapples with this question as demand grows.